{"protocolSection":{"identificationModule":{"nctId":"NCT06476808","orgStudyIdInfo":{"id":"CA231-0000"},"organization":{"fullName":"Bristol-Myers Squibb","class":"INDUSTRY"},"briefTitle":"A Study to Evaluate the Safety, Tolerability, and Efficacy of Escalating Doses of BMS-986463 in Participants With Select Advanced Malignant Tumors.","officialTitle":"A Phase 1/1b First-in-human Study of BMS-986463 in Advanced Malignant Tumors"},"statusModule":{"statusVerifiedDate":"2024-06","overallStatus":"NOT_YET_RECRUITING","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2024-07-31","type":"ESTIMATED"},"primaryCompletionDateStruct":{"date":"2028-12-19","type":"ESTIMATED"},"completionDateStruct":{"date":"2028-12-19","type":"ESTIMATED"},"studyFirstSubmitDate":"2024-06-21","studyFirstSubmitQcDate":"2024-06-21","studyFirstPostDateStruct":{"date":"2024-06-26","type":"ACTUAL"},"lastUpdateSubmitDate":"2024-06-21","lastUpdatePostDateStruct":{"date":"2024-06-26","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Bristol-Myers Squibb","class":"INDUSTRY"}},"oversightModule":{"oversightHasDmc":false,"isFdaRegulatedDrug":true,"isFdaRegulatedDevice":false},"descriptionModule":{"briefSummary":"The purpose of this study is to evaluate the safety, tolerability, and efficacy of escalating doses of BMS-986463 in participants with select advanced malignant tumors."},"conditionsModule":{"conditions":["High-grade Serous Ovarian Carcinoma (HGSOC)","Uterine Serous Carcinoma (USC)","Non-small Cell Lung Cancer (NSCLC)"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE1"],"designInfo":{"allocation":"NON_RANDOMIZED","interventionModel":"SEQUENTIAL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"NONE"}},"enrollmentInfo":{"count":240,"type":"ESTIMATED"}},"armsInterventionsModule":{"armGroups":[{"label":"Arm 1: Dose Escalation","type":"EXPERIMENTAL","interventionNames":["Drug: BMS-986463"]},{"label":"Arm 2: Dose Expansion","type":"EXPERIMENTAL","interventionNames":["Drug: BMS-986463"]}],"interventions":[{"type":"DRUG","name":"BMS-986463","description":"Specified dose on specified days","armGroupLabels":["Arm 1: Dose Escalation","Arm 2: Dose Expansion"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Number of participants with adverse events (AEs)","timeFrame":"Up to 108 weeks"},{"measure":"Number of participants with serious adverse events (SAEs)","timeFrame":"Up to 108 weeks"},{"measure":"Number of participants with AEs meeting protocol defined dose-limiting toxicity (DLT) criteria","timeFrame":"Up to 108 weeks"},{"measure":"Number of participants with AEs leading to discontinuation","timeFrame":"Up to 108 weeks"},{"measure":"Number of participants with AEs leading to death","timeFrame":"Up to 108 weeks"}],"secondaryOutcomes":[{"measure":"Maximum observed concentration (Cmax)","timeFrame":"Up to 104 weeks"},{"measure":"Area under the concentration-time curve (AUC)","timeFrame":"Up to 104 weeks"},{"measure":"Time of maximum observed concentration (Tmax)","timeFrame":"Up to 104 weeks"},{"measure":"Objective response rate (ORR)","timeFrame":"Up to 104 weeks"},{"measure":"Disease control rate (DCR)","timeFrame":"Up to 104 weeks"},{"measure":"Duration of response (DOR)","timeFrame":"Up to 104 weeks"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria\n\n* Participants must have an Eastern Cooperative Oncology Group Performance Status of 0 or 1.\n* Participants must have at least 1 lesion accessible for biopsy in addition to the target lesion, from which a fresh pre treatment biopsy must be obtained.\n* Participants must have an unresectable/metastatic carcinoma.\n\nExclusion Criteria\n\n* Participants must not have Leptomeningeal metastases.\n* Participants must not have concurrent malignancy (present during screening) requiring treatment or history of prior malignancy active within 2 years prior to treatment.\n* Participants must not have had any prior radiation therapy within 2 weeks prior to start of study treatment.\n* Other protocol-defined Inclusion/Exclusion criteria apply.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"centralContacts":[{"name":"BMS Study Connect www.BMSStudyConnect.com","role":"CONTACT","phone":"855-907-3286","email":"Clinical.Trials@bms.com"},{"name":"First line of the email MUST contain the NCT# and Site#","role":"CONTACT"}],"overallOfficials":[{"name":"Bristol-Myers Squibb","affiliation":"Bristol-Myers Squibb","role":"STUDY_DIRECTOR"}],"locations":[{"facility":"Local Institution - 0003","city":"Los Angeles","state":"California","zip":"90033","country":"United States","contacts":[{"name":"Site 0003","role":"CONTACT"}],"geoPoint":{"lat":34.05223,"lon":-118.24368}},{"facility":"Local Institution - 0014","city":"Los Angeles","state":"California","zip":"90033","country":"United States","geoPoint":{"lat":34.05223,"lon":-118.24368}},{"facility":"Local Institution - 0006","city":"Los Angeles","state":"California","zip":"90067","country":"United States","contacts":[{"name":"Site 0006","role":"CONTACT"}],"geoPoint":{"lat":34.05223,"lon":-118.24368}},{"facility":"Local Institution - 0017","city":"Los Angeles","state":"California","zip":"90067","country":"United States","geoPoint":{"lat":34.05223,"lon":-118.24368}},{"facility":"Local Institution - 0015","city":"Aurora","state":"Colorado","zip":"80045","country":"United States","geoPoint":{"lat":39.72943,"lon":-104.83192}},{"facility":"University of Colorado Anschutz Medical Campus","city":"Aurora","state":"Colorado","zip":"80045","country":"United States","geoPoint":{"lat":39.72943,"lon":-104.83192}},{"facility":"Local Institution - 0020","city":"New Haven","state":"Connecticut","zip":"06510","country":"United States","geoPoint":{"lat":41.30815,"lon":-72.92816}},{"facility":"Yale-New Haven Hospital","city":"New Haven","state":"Connecticut","zip":"06510","country":"United States","geoPoint":{"lat":41.30815,"lon":-72.92816}},{"facility":"Local Institution - 0018","city":"Atlanta","state":"Georgia","zip":"30322","country":"United States","geoPoint":{"lat":33.749,"lon":-84.38798}},{"facility":"Local Institution - 0023","city":"Atlanta","state":"Georgia","zip":"30322","country":"United States","geoPoint":{"lat":33.749,"lon":-84.38798}},{"facility":"Winship Cancer Institute of Emory University","city":"Atlanta","state":"Georgia","zip":"30322","country":"United States","geoPoint":{"lat":33.749,"lon":-84.38798}},{"facility":"Local Institution - 0021","city":"Baltimore","state":"Maryland","zip":"21287","country":"United States","geoPoint":{"lat":39.29038,"lon":-76.61219}},{"facility":"Dana-Farber Cancer Institute","city":"Boston","state":"Massachusetts","zip":"02215","country":"United States","geoPoint":{"lat":42.35843,"lon":-71.05977}},{"facility":"Local Institution - 0016","city":"Boston","state":"Massachusetts","zip":"02215","country":"United States","geoPoint":{"lat":42.35843,"lon":-71.05977}},{"facility":"Local Institution - 0022","city":"Boston","state":"Massachusetts","zip":"02215","country":"United States","geoPoint":{"lat":42.35843,"lon":-71.05977}},{"facility":"Local Institution - 0019","city":"Saint Louis","state":"Missouri","zip":"63110","country":"United States","geoPoint":{"lat":38.62727,"lon":-90.19789}},{"facility":"Local Institution - 0001","city":"Hackensack","state":"New Jersey","zip":"07601","country":"United States","contacts":[{"name":"Site 0001","role":"CONTACT"}],"geoPoint":{"lat":40.88593,"lon":-74.04347}},{"facility":"Local Institution - 0013","city":"Hackensack","state":"New Jersey","zip":"07601","country":"United States","geoPoint":{"lat":40.88593,"lon":-74.04347}},{"facility":"Local Institution - 0025","city":"Edmonton","state":"Alberta","zip":"T6G 1Z2","country":"Canada","contacts":[{"name":"Site 0025","role":"CONTACT"}],"geoPoint":{"lat":53.55014,"lon":-113.46871}},{"facility":"Local Institution - 0026","city":"Vancouver","state":"British Columbia","zip":"V5Z 4E6","country":"Canada","contacts":[{"name":"Site 0026","role":"CONTACT"}],"geoPoint":{"lat":49.24966,"lon":-123.11934}},{"facility":"Local Institution - 0027","city":"Toronto","state":"Ontario","zip":"M5G 2M9","country":"Canada","contacts":[{"name":"Site 0027","role":"CONTACT"}],"geoPoint":{"lat":43.70011,"lon":-79.4163}},{"facility":"Local Institution - 0024","city":"Montreal","state":"Quebec","zip":"H3T 1E2","country":"Canada","contacts":[{"name":"Site 0024","role":"CONTACT"}],"geoPoint":{"lat":45.50884,"lon":-73.58781}}]},"referencesModule":{"seeAlsoLinks":[{"label":"BMS Clinical Trial Information","url":"https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html"},{"label":"BMS Clinical Trial Patient Recruiting","url":"https://www.BMSClinicalTrials.com"},{"label":"FDA Safety Alerts and Recalls","url":"http://www.fda.gov/MEDWATCH/safety.htm"}]},"ipdSharingStatementModule":{"ipdSharing":"YES","description":"BMS will provide access to individual anonymized participant data upon request from qualified researchers, and subject to certain criteria. Additional information regarding Bristol Myer Squibb's data sharing policy and process can be found at: https://www.bms.com/researchers-and-partners/clinical-trials-and-research/disclosure-commitment.html","infoTypes":["STUDY_PROTOCOL","SAP","CSR"],"timeFrame":"See plan description","accessCriteria":"See plan description","url":"https://www.bms.com/researchers-and-partners/clinical-trials-and-research/disclosure-commitment.html"}},"derivedSection":{"miscInfoModule":{"versionHolder":"2024-07-01"},"conditionBrowseModule":{"meshes":[{"id":"D000002277","term":"Carcinoma"},{"id":"D000018284","term":"Cystadenocarcinoma, Serous"}],"ancestors":[{"id":"D000009375","term":"Neoplasms, Glandular and Epithelial"},{"id":"D000009370","term":"Neoplasms by Histologic Type"},{"id":"D000009369","term":"Neoplasms"},{"id":"D000003536","term":"Cystadenocarcinoma"},{"id":"D000000230","term":"Adenocarcinoma"},{"id":"D000018297","term":"Neoplasms, Cystic, Mucinous, and Serous"}],"browseLeaves":[{"id":"M5534","name":"Carcinoma","asFound":"Carcinoma","relevance":"HIGH"},{"id":"M12974","name":"Ovarian Neoplasms","relevance":"LOW"},{"id":"M1704","name":"Carcinoma, Ovarian Epithelial","relevance":"LOW"},{"id":"M11172","name":"Lung Neoplasms","relevance":"LOW"},{"id":"M5546","name":"Carcinoma, Non-Small-Cell Lung","relevance":"LOW"},{"id":"M20429","name":"Cystadenocarcinoma, Serous","asFound":"Serous Carcinoma","relevance":"HIGH"},{"id":"M6741","name":"Cystadenocarcinoma","relevance":"LOW"},{"id":"M12320","name":"Neoplasms, Glandular and Epithelial","relevance":"LOW"},{"id":"M12315","name":"Neoplasms by Histologic Type","relevance":"LOW"},{"id":"M3585","name":"Adenocarcinoma","relevance":"LOW"},{"id":"M20441","name":"Neoplasms, Cystic, Mucinous, and Serous","relevance":"LOW"},{"id":"T4352","name":"Ovarian Cancer","relevance":"LOW"},{"id":"T4354","name":"Ovarian Epithelial Cancer","relevance":"LOW"},{"id":"T200","name":"Adenocarcinoma of the Appendix","relevance":"LOW"}],"browseBranches":[{"abbrev":"BC04","name":"Neoplasms"},{"abbrev":"All","name":"All Conditions"},{"abbrev":"BXS","name":"Urinary Tract, Sexual Organs, and Pregnancy Conditions"},{"abbrev":"BC19","name":"Gland and Hormone Related Diseases"},{"abbrev":"BC08","name":"Respiratory Tract (Lung and Bronchial) Diseases"},{"abbrev":"Rare","name":"Rare Diseases"}]}},"hasResults":false}